Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02343991 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Blood-Brain Barrier Disruption Using Transcranial MRI-Guided Focused Ultrasound

StatusActive, Not Recruiting
PhaseNot applicable
SponsorInSightec
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 2021 to Dec 2026 Completion date: Jul 2022 to Dec 2026v9 Show 1 more changeShow less
    • Completion date: Jul 2022 to Dec 2026
  2. Primary completion date: Dec 2020 to Dec 2021 Completion date: Jul 2021 to Jul 2022v8 Show 1 more changeShow less
    • Completion date: Jul 2021 to Jul 2022
  3. Primary completion date: Dec 2019 to Dec 2020 Completion date: Dec 2019 to Jul 2021v7 Show 1 more changeShow less
    • Completion date: Dec 2019 to Jul 2021
  4. Primary and study completion dates: Dec 2018 to Dec 2019 Trial status: Recruiting to Active, Not Recruiting · Site details revisedv6 Show 2 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
  5. Primary and study completion dates: Dec 2017 to Dec 2018v5
Show 3 earlier versionsHide 3 earlier versions
  1. Primary and study completion dates: Dec 2016 to Dec 2017 Site contact updatedv4 Show 1 more changeShow less
    • Site contact updated
  2. Primary and study completion dates: Dec 2015 to Dec 2016v3
  3. Site contact updatedv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
InSightec
42 trials monitored
See 1 trial at risk
The purpose of this study is to evaluate the safety of BBB disruption using transcranial MRI-guided focused ultrasound in conjunction with an intravenous ultrasound contrast agent to increase the accumulation of doxorubicin in brain tumours and the adjacent brain using the ExAblate Transcranial system (220 kHz). Data will be collected to establish the basic safety of this type of treatment as the basis for later studies to evaluate its clinical efficacy.
Trial Details
NCT Number NCT02343991
Lead Sponsor InSightec
Conditions Brain Tumor
Enrollment 10 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov